CheckMyRecalls

Direct Rx recalls DULOXETINE D/R

Published
1 Jul 2026
Units affected
263 Bottles
Agency
FDA
Country
United States

The hazard

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBALTA, Packaged and Distributed by Direct Rx.

Brand / company
Direct Rx
Codes / lots
Lot: a) 09JA2530, 31JA2507, expires: 04/30/2027; b) Lot: 09DE2412, 09JA2528, 29JA2511, expires: 04/30/2027.
Distribution
U.S. Nationwide
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 1 Jul 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.